What are the treatment options for patients with interstitial cystitis?


Because the etiology of interstitial cystitis remains unknown and the pathogenesis has not been clarified, the current treatment focuses on decreasing symptoms and achieving remission. Various types of pharmacotherapy and surgical manipulations have been tried with varying degrees of success. Among the latter, cystoscopic hydrodistention may provide only temporary relief, and cystectomy and urinary diversion have an unacceptable high failure rate for pain control. Standard pharmacotherapy with a tricyclic antidepressant (amitriptyline), intravesical dimethylsulfoxide, anticholinergics, antihistamines, cyclosporin A, and pentosan polysulfate sodium has been tested with some effects but also often with significant side effects. Although at this time all encouraging data are limited to animal studies, antineuropeptide therapy appears to offer the best hope. According to recent studies, neuromodulation via direct stimulation of the sacral nerves is another approach with lasting favorable results.


Interstitial Cystitis Sacral Nerve Stimulation Pentosan Polysulfate Sacral Nerve Root Pontine Micturition Center 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Parkin J, Shea C, Sant GR (1997) Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis: a practical approach. Urology 49(suppl): 105–107.PubMedCrossRefGoogle Scholar
  2. 2.
    Perez-Marrero R, Emmerson LE, Feltis JT (1988) A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol 140: 36–39.PubMedGoogle Scholar
  3. 3.
    Stout L, Gerspach JM, Levy SM, Yun SK, Lad PM, Leach GE, Zimmern PE (1995) Dimethyl sulfoxide does not trigger urine histamine release in interstitial cystitis. Urology 46: 653–656.PubMedCrossRefGoogle Scholar
  4. 4.
    Sant GR (1987) Intravesical 50% dimethyl sulfoxide (RIMSO-50) in treatment of interstitial cystitis. Urology 29(suppl):17–21.PubMedGoogle Scholar
  5. 5.
    Selo-Ojeme DO, Onwude JL (2004) Interstitial cystitis. J Obstet Gynecol 24: 216–225.Google Scholar
  6. 6.
    Jacob SW, Hershler R (1975) Biological actions of dimethyl sulfoxide. Ann N Y Acad Sci 243: 497–503.CrossRefGoogle Scholar
  7. 7.
    Hanno PM, Wein AJ (1987) Medical treatment of interstitial cystitis (other than Rimso-50/Elmiron). Urology 29 (suppl):22–26.PubMedGoogle Scholar
  8. 8.
    Van Ophoven A, Pokupic S, Heinecke A, Hertle L (2004) A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol 172: 533–536.PubMedCrossRefGoogle Scholar
  9. 9.
    Parsons CL, Schmidt JD, Pollen JJ (1983) Successful treatment of interstitial cystitis with sodium pentosan-polysulfate. J Urol 130: 51–53.PubMedGoogle Scholar
  10. 10.
    Parsons CL, Mulholland SG (1987) Successful therapy of interstitial cystitis with pentosanpolysulfate. J Urol 138: 513–516.PubMedGoogle Scholar
  11. 11.
    Bade JJ, Mensink HJA, Laseur M (1995) Intravesical treatment of interstitial cystitis with a heparin analogue. Br J Urol 75: 260.PubMedGoogle Scholar
  12. 12.
    Parsons CL, Housley JD, Schmidt JD, Lebow D (1994) Treatment of interstitial cystitis with intravesical heparin. Br J Urol 73: 504–507.PubMedCrossRefGoogle Scholar
  13. 13.
    Holm-Bentzen M, Jacobsen F, Nerstrom B, Lose G, Kristensen JK, Pedersen RH, Krarup T, Feggetter J, Bates P, Barnard R, Larsen S, Hald T (1987) A prospective double blind clinically controlled multicenter trial of sodium pentosan polysulfate in the treatment of interstitial cystitis and related painful bladder disease. J Urol 138: 503–507.PubMedGoogle Scholar
  14. 14.
    Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR (1990) Pentosan polysulfate sodium for therapy of interstitial cystitis: a double-blind placebo-controlled clinical study. Urology 35: 552–558.PubMedCrossRefGoogle Scholar
  15. 15.
    Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, Hardy C, Landis JR, Mayer R, Madugan R, Messing EM, Peters K, Theoharides TC, Warren J, Wein AJ, Steers W, Kusek JW, Nyberg LM: the Interstitial Cystitis Clinical Trials Group (2003) A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol 170: 810–815.Google Scholar
  16. 16.
    Nickel JC, Barkin J, Forrest J, Mosbaugh PG, Hernandez-Graulau J, Kaufman D, Lloyd K, Evans RJ, Parsons CL, Atkinson LE (2005) Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 65: 654–658.PubMedCrossRefGoogle Scholar
  17. 17.
    Hwang P, Auclair B, Beechinor D, Diment M, Einarson TR (1997) Efficacy of pentosan polysulfate in the treatment of interstitial cystitis: a meta-analysis. Urology 50: 39–43.PubMedCrossRefGoogle Scholar
  18. 18.
    Elbadawi AE, Light JK (1996) Distinctive ultrastructural pathology of nonulcerative interstitial cystitis: new observations and their potential significance in pathogenesis. Urol Int 56: 137–162.PubMedCrossRefGoogle Scholar
  19. 19.
    Sairanen J, Tammela TLJ, Leppilahti M, Multanen M, Paananen I, Lehtoranta K, Ruutu M (2005) Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol 174: 2235–2238.PubMedCrossRefGoogle Scholar
  20. 20.
    Zeidman EJ, Helfrick B, Pollard C, Thompson IM (1994) Bacillus Calmette-Guerin immunotherapy for refractory interstitial cystitis. Urology 43: 121–124.PubMedCrossRefGoogle Scholar
  21. 21.
    Peters KM, Diokno AC, Steinert BW, Gonzalez JA (1998) The efficacy of intravesical bacillus Calmette-Guerin in the treatment of interstitial cystitis: long-term followup. J Urol 159: 1483–1486.PubMedCrossRefGoogle Scholar
  22. 22.
    Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, Culkin DJ, Diokno A, Hanno P, Landis JR, Madigan R, Messing EM, Nickel JC, Sant GR, Warren J, Wein AJ, Kusek JW, Nyberg LM, Foster HE: the Interstitial Cystitis Clinical Trials Group (2005) A randomized controlled trial of intravesical bacillus Calmette-Guerin for treatment refractory interstitial cystitis. J Urol 173: 1186–1191.Google Scholar
  23. 23.
    Callsen-Cancic P, Mense S (1997) Expression of neu-ropeptides and nitric acid synthase in neurones innervating the inflamed rat bladder. J Auton Nerv Syst 65: 33–44.CrossRefGoogle Scholar
  24. 24.
    Gonzalez RR, Fong T, Belmar N, Saban M, Felsen D, Te A (2005) Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis. J Urol 173: 630–634.PubMedCrossRefGoogle Scholar
  25. 25.
    Murthy S, Flannigan A, Coppola D, Buelow R (2002) RDP58, a locally active TNF inhibitor, is effective in the dextran sulfate mouse model of chronic colitis. Inflamm Res 51: 522–531.PubMedCrossRefGoogle Scholar
  26. 26.
    Zhao J, Huang L, Belmar N, Buelow R, Fong T (2004) Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res 10: 2851–2859.PubMedCrossRefGoogle Scholar
  27. 27.
    Chancellor MB, De Groat WC (1999) Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 162: 3–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Smith SD, Wheeler MA, Foster HE Jr, Weiss RM (1997) Improvement in interstitial cystitis symptom scores during treatment with oral l-arginine. J Urol 158: 703–708.PubMedCrossRefGoogle Scholar
  29. 29.
    Korting GE, Smith SD, Wheeler MA, Weiss RM, Foster HE Jr (1999) A randomized double-blind trial of oral l-arginine for treatment of interstitial cystitis. J Urol 161: 558–565.PubMedCrossRefGoogle Scholar
  30. 30.
    Wilsoncroft P, Euzger H, Brain SD (1994) Effect of a neurokinin-1 (NK1) receptor antagonist on oedema formation induced by tachykinins, carrageenin and an allergic response in guinea-pig skin. Neuropeptides 26: 405–411.PubMedCrossRefGoogle Scholar
  31. 31.
    Schmidt RA, Senn E, Tanagho EA (1990) Functional evaluation of sacral nerve root integrity: report of a technique. Urology 35: 388–392.PubMedCrossRefGoogle Scholar
  32. 32.
    Comiter CV (2003) Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study. J Urol 169: 1369–1373.PubMedCrossRefGoogle Scholar
  33. 33.
    de Groat WC (1996) Neuroanatomy and neurophysiology: innervation of the lower urinary tract. In: Raz S (ed) Female urology. Saunders, Philadelphia, pp 28–42.Google Scholar
  34. 34.
    Maher CF, Carey MP, Dwyer PL, Schulter PL (2001) Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis. J Urol 165: 884–886.PubMedCrossRefGoogle Scholar
  35. 35.
    Yokozuka M, Namima T, Nakagawa H, Ichie M, Handa Y (2004) Effects and indications of sacral surface therapeutic electrical stimulation in refractory urinary incontinence. Clin Rehabil 18: 899–907.PubMedCrossRefGoogle Scholar
  36. 36.
    Fall M (1985) Conservative management of chronic interstitial cystitis: transcutaneous electrical nerve stimulation and transurethral resection. J Urol 133: 774–778.PubMedGoogle Scholar
  37. 37.
    Peters KM, Konstandt D (2004) Sacral neuromodulation decreases narcotic requirements in refractory interstitial cystitis. BJU Int 93: 777–779.PubMedCrossRefGoogle Scholar
  38. 38.
    Chai TC, Zhang C-O, Warren JW, Keay S (2004) Percutaneous sacral third nerve root neurostimulation improves symptoms and normalizes urinary HB-EFG levels and antiproliferative activity in patients with interstitial cystitis. BJU Int 93: 777–779.CrossRefGoogle Scholar

Copyright information

© Springer 2008

Personalised recommendations